In this respect, three papers compared Sanger sequencing with the Cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc.), an FDA-approved real-time PCR assay to select patients with metastatic melanoma for treatment with the selective BRAF inhibitor vemurafenib or with cobimetinib plus vemurafenib combination (Lopez-Rios et al., 2013; Qu et al., 2013; Jurkowska et al., 2015). This evidence concerns the gene BRAF and metastatic melanoma.